SEC Form SC 13G/A filed by Waters Corporation (Amendment)

2/14/24 9:37:22 AM ET

Biotechnology: Laboratory Analytical Instruments

Industrials

Get the next $WAT alert in real time by email

SC 13G/A 1 fundsmith_waters2023.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.:6 Name of Issuer: Waters CORP Title of Class of Securities: Common Stock CUSIP Number: 941848103 (Date of Event Which Requires Filing of this Statement) December 31, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: /X/ Rule 13d-l(b) / / Rule 13d-l(c) / / Rule 13d-l(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP Number: 941848103 1. Name of Reporting Person Fundsmith LLP 2. Check the Appropriate Box if a Member of a Group a. /X/ b. / / 3. SEC Use Only 4. Citizenship or Place of Organization United Kingdom Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power: 4,917,502 6. Shared Voting Power: NONE 7. Sole Dispositive Power: 4,935,371 8. Shared Dispositive Power: NONE 9. Aggregate Amount Beneficially Owned by Each Reporting Person 4,935,371 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares / / 11. Percent of Class Represented by Amount in Row (9) 8.30% 12. Type of Reporting Person IA -2- Item 1(a) Name of Issuer: Waters CORP (b) Address of Issuer's Principal Executive Offices: 34 Maple Street, Milford MA 01757, United States Item 2(a) - (c). Name, Principal Business Address, and Citizenship of Persons Filing: Fundsmith LLP 33 Cavendish Square, London, UK, W1G 0PW (d) Title of Class of Securities: Common Stock (e) CUSIP Number: 941848103 Item 3. This statement is filed pursuant to Rule 13d-1(b)(1). /x/ Group, in accordance with Rule 13d-1(b)(1) (ii)(K) Item 4. Ownership. (a) Amount Beneficially Owned: 4,935,371 (b) Percent of Class: 8.30% (c) (i) shares with sole power to vote or direct the vote: 4,917,502 (ii) shared power to vote or direct the vote: NONE (iii) shares with sole power to dispose or to direct the disposition of: 4,935,371 (iv) shares with shared power to dispose or direct the disposition of: NONE Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following / /. Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A -3- Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company. N/A Item 8. Identification and Classification of Members of the Group. See Exhibit 1 Item 9. Notice of Dissolution of the Group. N/A Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to Investment Adviser is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, inforamtion that would otherwise be disclosed in a Schedule 13D. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. By: /s/ Tom Armstrong February 14, 2024 _________________________ _________________ Title: Director Date

Get the next $WAT alert in real time by email

Recent Analyst Ratings for

$WAT

Date	Price Target	Rating	Analyst
3/31/2025	$460.00	Sector Weight → Overweight	KeyBanc Capital Markets
3/26/2025	$396.00 → $407.00	Neutral → Outperform	Robert W. Baird
2/13/2025	$450.00	Sector Perform → Sector Outperform	Scotiabank
2/10/2025	$360.00 → $415.00	Underweight → Equal Weight	Barclays
1/10/2025	$430.00	Mkt Perform → Outperform	Bernstein
12/23/2024		Sector Perform	Scotiabank
10/8/2024	$355.00 → $415.00	Hold → Buy	Jefferies
8/28/2024	$380.00	Overweight	Wells Fargo

More analyst ratings

SEC Form SC 13G/A filed by Waters Corporation (Amendment)

Chat with this insight

Recent Analyst Ratings for
$WAT

$WAT
Press Releases

Fastest customizable press release news feed in the world

Waters Introduces BioResolve Protein A Affinity Columns to Accelerate Antibody Titer Measurement, Enhancing Process Agility and Batch Quality

Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

Waters Corporation to Present at the Jefferies Global Healthcare Conference

$WAT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SVP & Chief Financial Officer Chaubal Amol covered exercise/tax liability with 239 shares, decreasing direct ownership by 4% to 5,224 units (SEC Form 4)

SVP TA Instruments Division Bennett Jianqing covered exercise/tax liability with 303 shares, decreasing direct ownership by 6% to 4,916 units (SEC Form 4)

Director Jiang Wei was granted 53 shares, increasing direct ownership by 2% to 2,410 units (SEC Form 4)

$WAT
Leadership Updates

Live Leadership Updates

Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

Waters Corporation Appoints Heather Knight to Board of Directors

Waters Corporation Appoints Richard Fearon to Board of Directors

$WAT
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Fearon Richard H bought $332,900 worth of shares (1,000 units at $332.90), increasing direct ownership by 153% to 1,653 units (SEC Form 4)

$WAT
Financials

Live finance-specific insights

Waters Corporation (NYSE: WAT) Reports First Quarter 2025 Financial Results

STAAR Surgical Announces Changes to Board of Directors

Waters Corporation Schedules First Quarter 2025 Earnings Conference Call

$WAT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Waters upgraded by KeyBanc Capital Markets with a new price target

Waters upgraded by Robert W. Baird with a new price target

Waters upgraded by Scotiabank with a new price target

$WAT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Waters Corporation